NCT04616560 2026-03-18Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent OsteosarcomaNational Cancer Institute (NCI)Phase 2 Suspended77 enrolled
NCT04539366 2025-11-03Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST TrialNational Cancer Institute (NCI)Phase 1 Suspended67 enrolled